Belzutifan tablets | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Welireg
- Company
- Merck Sharp & Dohme B.V. (EU authorization holder)
- Medicine type
- Chemical medicine
- Therapeutic area
- Oncology
- Indications recorded in the public source
- European Union source summary: Monotherapy for adults with advanced clear-cell renal cell carcinoma progressing after at least two treatment lines that included a PD-(L)1 inhibitor and at least two VEGF-targeted therapies. Also for adults with von Hippel-Lindau disease requiring treatment for localized associated renal cell carcinoma, CNS hemangioblastomas or pancreatic neuroendocrine tumors when local procedures are unsuitable.
- Indication source and scope
- European Union product information accessed 2 November 2026; exact revision date not separately extracted.. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.ema.europa.eu/en/documents/product-information/welireg-epar-product-information_en.pdf
- Welireg — official European Union product information
Official prescribing information · European Union product information accessed 2 November 2026; exact revision date not separately extracted.
Full official PDF opened; medicine identity and relevant indication text checked. This overseas source does not establish the Chinese approved scope.
- Welireg — EMA assessment and product overview
Regulatory product overview · Accessed 2 November 2026
English regulatory reference; authorization holder is identified for the EU product, not a Chinese generic or biosimilar.
- FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- Shenzhen New Frontier United Family Hospital — public prices
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions